US FDA Manufacturing Enforcement In Brief: Recent Warning Letters And Import Alerts
Executive Summary
Recent US FDA drug GMP warning letters featured findings of lax contamination controls and data integrity issues at firms in China, India, Japan, Illinois and East Texas. Meanwhile, FDA hit six plants in India and China with drug GMP import alerts.